| Study | Treatment 1 | Treatment 2 | ROM | 95% CI lower limit | 95% CI upper limit |
| Abril‐Molina 2021 | Levosimendan | Placebo | 1.1736 | 0.6482 | 2.1248 |
| Cavigelli‐Brunner 2018 | Dobutamine | Milrinone | 0.8257 | 0.4320 | 1.5780 |
| Costello 2014 | Milrinone | Placebo | 1.2541 | 0.6669 | 2.3583 |
| Ebade 2013 | Dobutamine | Levosimendan | 0.8823 | 0.4747 | 1.6399 |
| Jothinath 2021 | Levosimendan | Milrinone | 0.9358 | 0.6262 | 1.3985 |
| Lechner 2012 | Levosimendan | Milrinone | 0.9358 | 0.6262 | 1.3985 |
| Momeni 2011 | Levosimendan | Milrinone | 0.9358 | 0.6262 | 1.3985 |
| Thorlacius 2020 | Levosimendan | Milrinone | 0.9358 | 0.6262 | 1.3985 |
| Wang 2019 | Levosimendan | Placebo | 1.1736 | 0.6482 | 2.1248 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.